Articles from Ibex Medical Analytics

Ibex Medical Analytics (Ibex), the global leader in clinical-grade AI-powered pathology, today announced the launch of Ibex 4, its next-generation platform. Built on Ibex’s clinically validated algorithms1-10 and developed in close collaboration with the world’s leading pathology labs, Ibex 4 is designed to transform the diagnostic journey, delivering unprecedented value to pathologists, laboratories, and patients.

Ibex Medical Analytics (Ibex), the global leader in clinical-grade AI-powered pathology, today announced continued commercial momentum and expanding global adoption alongside a leadership transition designed to accelerate the company’s next phase of growth. Effective immediately, Yair Heller, formerly Chief Operating Officer, has been appointed Chief Executive Officer, and co-founder Joseph Mossel will lead Ibex’s rapidly expanding biopharma division and U.S. clinical growth initiatives.

Ibex Medical Analytics, the global leader in clinical-grade AI-powered pathology, today announced a significant expansion of its biopharma business. Building on its successful collaborations in late-stage biomarker development, Ibex is now extending its platform into earlier translational research, biomarker development, and trial-efficiency optimization.

Ibex Medical Analytics (Ibex), a leader in artificial intelligence (AI)-powered cancer diagnostics, today announced it has received In Vitro Diagnostic Medical Devices Regulation (IVDR) certification for its HER2 breast cancer biomarker scoring solution. Ibex’s fully automated “zero-click” AI-enhanced decision support tool for pathologists efficiently increases the accuracy and consistency of HER2 immunohistochemistry (IHC) scoring, including HER2-low cases. Ibex’s breast HER2 solution was developed and validated by Ibex in collaboration with AstraZeneca and Daiichi Sankyo.

A newly published peer-reviewed article on a study conducted at The Ohio State University Wexner Medical Center confirms that Ibex Breast, an AI-powered diagnostic support solution developed by Ibex Medical Analytics (Ibex), significantly improves accuracy and efficiency in evaluating breast pathology cases. The findings, published in Clinical Breast Cancer, demonstrate how AI technology can assist pathologists in providing patients with quicker and more trusted diagnostic results.

Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Ibex Prostate Detect, an in vitro diagnostic medical device that harnesses AI to generate heatmaps identifying small and rare missed prostatic cancers, acting as a safety net that assists pathologists in ensuring patients receive an accurate diagnosis.

Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, and Institut Curie, France’s globally renowned cancer center, today announced the introduction of Ibex’s AI solution in routine clinical practice. Pathologists at Institut Curie are now using Ibex’s AI tools when diagnosing prostate cancer to enhance accuracy, efficiency and improve patient outcomes; and plan to expand to a series of other Ibex applications in the coming months.

Ibex Medical Analytics (Ibex), the leader in artificial intelligence (AI)-powered cancer diagnostics, today announced the publication of a clinical study evaluating Ibex Breast HER2 in a peer-reviewed journal, JCO Precision Oncology.1 Showcasing the remarkable capabilities of Ibex’s AI technology, the manuscript, titled “Fully Automated Artificial Intelligence Solution for HER2 Immunohistochemistry Scoring in Breast Cancer: A Multireader Study”, demonstrates that this “zero-click” decision-support tool for pathologists results in highly accurate, reproducible, and efficient delineation of HER2 expression into four standard scores: 0, 1+, 2+ and 3+, based on the 2023 ASCO/CAP guidelines2, including the highly subjective and challenging HER2-low cases.

Ibex Medical Analytics (Ibex), the leader in artificial intelligence (AI)-powered cancer diagnostics, today announced the findings of its inaugural Patient Insight Report on Cancer Diagnostics. The survey explores patients’ perceptions of receiving medical diagnoses, particularly for cancer. The survey results underscore the importance of advanced cancer diagnostic technologies, as well as accurate test results, and gauges respondents’ comfort with AI.

Ibex Medical Analytics (Ibex), the leader in artificial intelligence (AI)-powered cancer diagnostics, today unveiled the latest advancements in its innovative product platform. These new features, developed in collaboration with expert pathologists around the world who use the product in routine clinical practice, underscore Ibex’s commitment to creating tools that meet the needs of those on the frontline of patient care.

Ibex Medical Analytics (Ibex), the leader in artificial intelligence (AI)-powered cancer diagnostics, today announced major advancements in customer growth, validation through a Quest Diagnostics study, regulatory approvals and expansion of its Board of Directors.

Alverno Laboratories, a provider of high-quality diagnostic testing services and one of the largest integrated laboratory networks in the United States, and Ibex Medical Analytics, the leader in artificial intelligence (AI)-powered cancer diagnostics, today announced the launch of the Ibex’s AI platform in routine practice within Alverno’s laboratory network in Illinois and Indiana. The phased launch encompasses AI-centric solutions for cancer diagnosis across multiple tissue types, including prostate, breast and gastric, that support pathologists and other physicians in providing the utmost quality of care for their patients. The laboratory system has recently completed phase 1 of its launch plan, enabling AI-powered prostate cancer detection for prostate biopsies, followed by breast and gastric.